Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

Rapamycin: an anti-cancer immunosuppressant?

Law BK.

Crit Rev Oncol Hematol. 2005 Oct;56(1):47-60. Review.

PMID:
16039868
2.

Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth.

Gibbons JJ, Abraham RT, Yu K.

Semin Oncol. 2009 Dec;36 Suppl 3:S3-S17. doi: 10.1053/j.seminoncol.2009.10.011. Review.

PMID:
19963098
3.

Mammalian target of rapamycin: a new molecular target for breast cancer.

Mita MM, Mita A, Rowinsky EK.

Clin Breast Cancer. 2003 Jun;4(2):126-37. Review.

PMID:
12864941
4.

The molecular target of rapamycin (mTOR) as a therapeutic target against cancer.

Mita MM, Mita A, Rowinsky EK.

Cancer Biol Ther. 2003 Jul-Aug;2(4 Suppl 1):S169-77. Review.

PMID:
14508096
5.

Mammalian target of rapamycin (mTOR) inhibitors as anti-cancer agents.

Rao RD, Buckner JC, Sarkaria JN.

Curr Cancer Drug Targets. 2004 Dec;4(8):621-35. Review.

PMID:
15578919
6.

Mammalian target of rapamycin is a promising target for novel therapeutic strategy against cancer.

Bjelogrlić SK, Srdić T, Radulović S.

J BUON. 2006 Jul-Sep;11(3):267-76. Review.

PMID:
17309148
7.

Phosphorylation of eIF4E by MNKs supports protein synthesis, cell cycle progression and proliferation in prostate cancer cells.

Bianchini A, Loiarro M, Bielli P, Busà R, Paronetto MP, Loreni F, Geremia R, Sette C.

Carcinogenesis. 2008 Dec;29(12):2279-88. doi: 10.1093/carcin/bgn221. Epub 2008 Sep 22.

PMID:
18809972
8.

A novel pathway regulating the mammalian target of rapamycin (mTOR) signaling.

Chen J, Fang Y.

Biochem Pharmacol. 2002 Oct 1;64(7):1071-7. Review.

PMID:
12234610
9.

Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma.

Francis LK, Alsayed Y, Leleu X, Jia X, Singha UK, Anderson J, Timm M, Ngo H, Lu G, Huston A, Ehrlich LA, Dimmock E, Lentzsch S, Hideshima T, Roodman GD, Anderson KC, Ghobrial IM.

Clin Cancer Res. 2006 Nov 15;12(22):6826-35.

10.

Targeting the Akt/mammalian target of rapamycin pathway for radiosensitization of breast cancer.

Albert JM, Kim KW, Cao C, Lu B.

Mol Cancer Ther. 2006 May;5(5):1183-9.

11.

Therapeutic potential of target of rapamycin inhibitors.

Easton JB, Houghton PJ.

Expert Opin Ther Targets. 2004 Dec;8(6):551-64. Review.

PMID:
15584862
12.

Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro.

Gorshtein A, Rubinfeld H, Kendler E, Theodoropoulou M, Cerovac V, Stalla GK, Cohen ZR, Hadani M, Shimon I.

Endocr Relat Cancer. 2009 Sep;16(3):1017-27. doi: 10.1677/ERC-08-0269. Epub 2009 Jun 9.

13.

mTOR pathway and mTOR inhibitors as agents for cancer therapy.

Baldo P, Cecco S, Giacomin E, Lazzarini R, Ros B, Marastoni S.

Curr Cancer Drug Targets. 2008 Dec;8(8):647-65. Review.

PMID:
19075588
14.

Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside.

Martelli AM, Tazzari PL, Evangelisti C, Chiarini F, Blalock WL, Billi AM, Manzoli L, McCubrey JA, Cocco L.

Curr Med Chem. 2007;14(19):2009-23. Review.

PMID:
17691943
15.

An expanding role for mTOR in cancer.

Guertin DA, Sabatini DM.

Trends Mol Med. 2005 Aug;11(8):353-61. Review.

PMID:
16002336
16.

The role of mTOR in the management of solid tumors: an overview.

Strimpakos AS, Karapanagiotou EM, Saif MW, Syrigos KN.

Cancer Treat Rev. 2009 Apr;35(2):148-59. doi: 10.1016/j.ctrv.2008.09.006. Epub 2008 Nov 14. Review.

PMID:
19013721
17.

Survival signaling by Notch1: mammalian target of rapamycin (mTOR)-dependent inhibition of p53.

Mungamuri SK, Yang X, Thor AD, Somasundaram K.

Cancer Res. 2006 May 1;66(9):4715-24.

19.

Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors.

Moreno A, Akcakanat A, Munsell MF, Soni A, Yao JC, Meric-Bernstam F.

Endocr Relat Cancer. 2008 Mar;15(1):257-66. doi: 10.1677/ERC-07-0202.

20.

Supplemental Content

Support Center